1-Cyclopenta-1,3-dienyl-2-methyl-propan-1-one | 79517-45-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Cyclopenta-1,3-dienyl-2-methyl-propan-1-one
• 英文别名: 1-Cyclopenta-1,3-dien-1-yl-2-methylpropan-1-one
• CAS: 79517-45-6
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: BKDCXPVOQQIIEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Cyclopenta-1,3-dienyl-2-methyl-propan-1-one 、 丁炔二酸二甲酯 生成 1-Isobutyryl-bicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylic acid dimethyl ester
  参考文献：
  名称：

  GRUNDKE, G.;HOFFMANN, H. M. R., J. ORG. CHEM., 1981, 46, N 26, 5428-5431

  摘要：

  DOI：
• 作为产物：
  描述：

  环戊二烯铊 、 isobutyryl iodide 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-Cyclopenta-1,3-dienyl-2-methyl-propan-1-one
  参考文献：
  名称：

  Synthesis and Diels-Alder reactions of 1-acylated 1,3-cyclopentadienes

  摘要：

  DOI：

  10.1021/jo00339a043

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
  申请人：RODGERS James D.

  公开号：US20120077798A1

  公开（公告）日：2012-03-29

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及氮杂环丙烷和环丁烷衍生物，以及它们的组合物，使用方法和制备方法，它们是JAK抑制剂，可用于治疗JAK相关疾病，包括炎症和自身免疫性疾病，以及癌症。
• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070117795A1

  公开（公告）日：2007-05-24

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及治疗由炎症反应引起的病理生理状况的方法和组合物。特别是，本发明涉及抑制或阻断糖基化蛋白质诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别是，本发明涉及通过调节HSPGs（如Perlecan）抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化。
• Methods and compositions for inhibition of Ras
  申请人：ARAXES PHARMA LLC

  公开号：US10011600B2

  公开（公告）日：2018-07-03

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了 Ras 蛋白的抑制剂、调节 Ras 蛋白活性的方法以及治疗由 Ras 蛋白介导的疾病的方法。描述了一种用化合物调节 K-Ras、H-Ras 或 N-Ras 突变蛋白活性的方法。可治疗的疾病包括癌症，如血癌、胰腺癌、MYH 相关性息肉病、结直肠癌或肺癌。
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.